New Alzheimer's Antibody Shows Fewer Blood Vessel Bindings Than Lecanemab
A lab study finds ACU193 binds less to brain blood vessels than lecanemab, potentially explaining differences in ARIA side effect risk.
Summary
Amyloid-targeting antibodies are a cornerstone of emerging Alzheimer's treatment, but a serious side effect called ARIA — involving brain swelling or bleeding — limits their use. Researchers compared lecanemab (FDA-approved) and ACU193 (sabirnetug, in clinical trials) by applying both antibodies to mouse brain tissue and measuring where each one binds. Lecanemab bound more extensively to cortical plaques and cerebellar blood vessels than ACU193, and covered a larger portion of total amyloid signal. Since vascular binding is thought to trigger ARIA, ACU193's lower vascular attachment may translate to a better safety profile. The study also found that tissue fixation time significantly affected how antibodies interact with amyloid, highlighting how lab protocol choices can influence results. These findings offer a molecular-level explanation for why different Alzheimer's antibodies carry different ARIA risks in patients.
Detailed Summary
Alzheimer's disease immunotherapy has advanced dramatically, but a troubling side effect — amyloid-related imaging abnormalities (ARIA), marked by brain swelling or microbleeds — limits how aggressively these treatments can be used. Understanding why some antibodies cause more ARIA than others is critical for improving patient safety and drug development.
Researchers from Brigham and Women's Hospital, Harvard Medical School, and Acumen Pharmaceuticals compared two anti-amyloid antibodies: lecanemab (brand name Leqembi, FDA-approved in 2023) and ACU193, also called sabirnetug, currently in clinical trials. The study used immunofluorescent staining — a technique that tags antibodies with fluorescent markers — applied to brain tissue from APP:hE4 mice, a model that develops both amyloid plaques and cerebral amyloid angiopathy (CAA, amyloid deposited in blood vessel walls).
The team found that lecanemab displayed significantly greater binding to cortical amyloid plaques and, importantly, to cerebellar blood vessels compared with ACU193. Lecanemab also labeled a larger fraction of total amyloid and beta-sheet-rich protein signal. ACU193, by contrast, showed more selective and restricted binding. Because vascular CAA binding is the leading hypothesis for how ARIA is triggered — through immune activation at blood vessel walls — ACU193's relatively lower vascular affinity may help explain its potentially more favorable ARIA profile seen in early clinical data.
A notable methodological finding was that tissue fixation time (30 minutes vs. 24 hours) significantly altered antibody-antigen interactions, meaning experimental protocols can meaningfully influence conclusions drawn about antibody binding.
These results suggest that antibody target selectivity — not just target abundance — shapes both therapeutic efficacy and safety risk. For clinicians, this research offers a mechanistic framework for understanding why ARIA rates differ across Alzheimer's drugs, and supports the rationale for developing antibodies that preferentially target soluble amyloid oligomers over vascular deposits.
Key Findings
- Lecanemab bound more extensively to brain blood vessels than ACU193, potentially explaining higher ARIA risk.
- ACU193 (sabirnetug) showed more selective amyloid binding, covering a smaller fraction of total amyloid signal.
- Vascular CAA binding by anti-amyloid antibodies is the proposed mechanism driving ARIA side effects.
- Tissue fixation time significantly altered antibody binding patterns, underscoring how lab protocols affect results.
- Antibody selectivity, not just target abundance, may be key to balancing Alzheimer's drug efficacy and safety.
Methodology
The study used immunofluorescent staining to compare ex vivo binding of recombinant lecanemab and ACU193 in APP:hE4 transgenic mouse brain tissue fixed for either 30 minutes or 24 hours. Binding was quantified across cortical plaques, cerebellar vasculature, and total amyloid signal including pan-Aβ and beta-sheet-rich deposits. The mouse model recapitulates both amyloid plaques and cerebral amyloid angiopathy relevant to Alzheimer's disease.
Study Limitations
This summary is based on the abstract only, as the full paper is not open access. The study used mouse brain tissue rather than human tissue, which may limit direct translation of binding patterns to clinical ARIA risk. Ex vivo immunofluorescence cannot fully replicate the dynamic in vivo interactions between circulating antibodies and brain vasculature.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.